[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Li et al., 2022 - Google Patents

Innate immune imprints in SARS-CoV-2 Omicron variant infection convalescents

Li et al., 2022

View HTML @Full View
Document ID
12937826759289270693
Author
Li Z
Chen X
Dan J
Hu T
Hu Y
Liu S
Chai Y
Shi Y
Wu J
Ni H
Zhu J
Wu Y
Li N
Yu Y
Wang Z
Zhao J
Zhong N
Ren X
Shen Z
Cao X
Publication year
Publication venue
Signal transduction and targeted therapy

External Links

Snippet

SARS-CoV-2 Omicron variant infection generally gives rise to asymptomatic to moderate COVID-19 in vaccinated people. The immune cells can be reprogrammed or “imprinted” by vaccination and infections to generate protective immunity against subsequent challenges …
Continue reading at www.nature.com (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Similar Documents

Publication Publication Date Title
Wen et al. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing
Kreutmair et al. Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia
Yao et al. Remodelling of the gut microbiota by hyperactive NLRP3 induces regulatory T cells to maintain homeostasis
Dhar et al. IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: results from meta-analysis and regression
Márquez et al. The lethal sex gap: COVID-19
Szabo et al. Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19
Ronit et al. Compartmental immunophenotyping in COVID-19 ARDS: A case series
Toussaint et al. Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation
Jackson et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2
Lingeswaran et al. Inflammation, immunity and immunogenetics in COVID-19: a narrative review
US11033588B2 (en) Compositions for treating inflammation and uses thereof
Singanayagam et al. Antiviral immunity is impaired in COPD patients with frequent exacerbations
Shen et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases
Ito et al. IL-22 induces Reg3γ and inhibits allergic inflammation in house dust mite–induced asthma models
Livanos et al. Gastrointestinal involvement attenuates COVID-19 severity and mortality
Lo Tartaro et al. Molecular and cellular immune features of aged patients with severe COVID-19 pneumonia
Li et al. Innate immune imprints in SARS-CoV-2 Omicron variant infection convalescents
Husein‐ElAhmed et al. Potential role of INTERLEUKIN‐17 in the pathogenesis of oral lichen planus: A systematic review with META‐analysis
Xie et al. High levels of soluble CD25 in COVID‐19 severity suggest a divergence between anti‐viral and pro‐inflammatory T‐cell responses
Hasan et al. Meta-analysis of single-cell RNA-seq data reveals phenotypic switching of immune cells in severe COVID-19 patients
Ruenjaiman et al. Impact of SARS-CoV-2 infection on the profiles and responses of innate immune cells after recovery
Baines et al. Azithromycin treatment modifies airway and blood gene expression networks in neutrophilic COPD
Dai et al. Characteristics of lymphocyte subset alterations in COVID-19 patients with different levels of disease severity
Martin-Sanchez et al. Immunological biomarkers of fatal COVID-19: a study of 868 patients
Lewis et al. Differential dynamics of peripheral immune responses to acute SARS-CoV-2 infection in older adults